Motilal Oswal
Sun Pharma Ind (Buy)
CMP: ₹754.45
Target: ₹875
Sun Pharmaceutical Industries’ Halol facility is already under quasi warning letter state as it received zero approvals over the last 15 months (since the US FDA inspection in September 2014), and corrective action plan started at this facility more than a year back. Though the company will have to augment its corrective measures to provide additional comfort to the US FDA, we believe remediation measures taken over last few months will help the company expedite the resolution process.
We have cut our FY17/18E EPS by 6 per cent and 3 per cent, respectively, as we build a delay of three to six months in resolution of Halol facility. Though earnings impact would be limited, we expect multiples to remain range-bound in the near term.
Sun Pharma has multiple catalysts ahead which (if played out well) could help limit the damage. Given that it is 15 months since the US FDA inspection at Halol, the probability of an import alert is low in our view.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.